2nd Quarter - Report
IKARIA for IKARIA
Firm
Client
Income
—
Expenses
$120,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
340B Drug Pricing Program; Critical Care Assessment and Improvement Act of 2013 (HR 2651); 21st Century Cures initiative
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE ELIZABETH ESPOSITO | — |
| LEAH DUFFY SVOBODA | — |
Medicare/Medicaid MMM
Non-interference; rebates; Protecting Seniors' Access to Medicare Act of 2013 (S 1316 and HR 351)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE ELIZABETH ESPOSITO | — |
| LEAH DUFFY SVOBODA | — |
Medical/Disease Research/Clinical Labs MED
Funding for rare disease research
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE ELIZABETH ESPOSITO | — |
| LEAH DUFFY SVOBODA | — |
Budget/Appropriations BUD
Deficit reduction/impact of sequestration on FDA and NIH; FDA Safety Over Sequestration Act of 2013 (HR 2725); FDA User Fee Protection Act (S 1413); FDA and BARDA/CDC appropriations.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE ELIZABETH ESPOSITO | — |
| LEAH DUFFY SVOBODA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.